Iranian Journal of Blood and Cancer,
Год журнала:
2022,
Номер
14(4), С. 125 - 139
Опубликована: Дек. 1, 2022
thrombotic
thrombocytopenia
(VITT)
Covid-19
vaccination
Platelet
factor
4(PF-4)The
common
reported
adverse
impacts
of
COVID-19
include
the
injection
site's
local
reaction
followed
by
various
non-specific
flu-like
symptoms.Nevertheless,
uncommon
cases
vaccine-induced
immune
and
cerebral
venous
sinus
thrombosis
(CVST)
following
viral
vector
vaccines
(ChAdOx1
nCoV-19
vaccine,
Ad26.COV2
vaccine)
have
been
reported.This
literature
review
was
performed
using
PubMed
Google
Scholar
databases
appropriate
keywords
their
combinations:
SARS-CoV-2,
adenovirus,
spike
protein,
thrombosis,
thrombocytopenia,
(VITT),
NF-kappaB,
adenoviral
vector,
platelet
4
(PF4),
Vaccine,
AstraZeneca
COVID
ChAdOx1
AZD1222
coagulopathy.The
abstracts
titles
each
article
were
assessed
authors
for
screening
inclusion
English
reports
about
post-vaccine
CVST
VITT
in
humans
also
collected.Some
SARS-CoV-2
based
on
mRNA,
or
inactivated
virus
accepted
are
being
pragmatic
global.Nevertheless,
recent
augmented
statistics
normally
very
infrequent
types
associated
with
stated,
predominantly
context
vaccine
from
Astra
Zeneca.The
numerical
prevalence
these
side
effects
seems
to
associate
this
particular
type,
i.e.,
vector-based
vaccines,
but
meticulous
molecular
mechanisms
still
not
clear.The
present
summarizes
latest
data
hypotheses
cellular
into
one
integrated
hypothesis
demonstrating
that
coagulopathies,
including
thromboses,
other
effects,
correlated
an
interaction
two
components
vaccine.
European Journal of Epidemiology,
Год журнала:
2024,
Номер
39(10), С. 1127 - 1138
Опубликована: Окт. 1, 2024
Abstract
This
study
evaluated
the
relationship
between
Covid-19
vaccination
and
menstrual
bleeding
disturbances
using
a
large
national
registry
linkage
including
666,467
women
20
40
years
of
age
residing
in
Norway
on
January
1st,
2019.
Information
vaccination—BNT162b2
mRNA-1273
—
was
obtained
from
Norwegian
registry.
Diagnoses
(absent/scanty,
excessive,
irregular/frequent
menstruation,
intermenstrual
bleeding)
general
practitioner
database.
We
examined
new-onset
Cox
regression
comparing
vaccinated
to
unvaccinated
women,
where
contributed
follow-up
time
as
until
day
vaccination.
In
addition,
we
conducted
self-controlled
case-series
analysis,
sensitivity
analysis
excluding
all
those
who
remained
throughout
pandemic,
evaluate
role
unmeasured
confounding.
observed
an
increased
risk
several
after
against
Covid-19,
ranging
adjusted
HR
(aHR)
1.18
(95%
CI:
1.04,
1.33)
for
1.29
1.23,
1.36)
periods.
However,
estimates
were
fully
attenuated
when
at
end
(aHRs
0.97
1.08).
No
differences
identified
according
vaccine
dose
or
type.
Our
case
series
confirmed
no
first
vaccination,
though
there
slightly
61
days
with
2.
conclusion,
modestly
appeared
reflect
confounding
by
never
received
vaccinations,
associations
did
not
remain
compared
before
among
ever
women.
Journal of Personalized Medicine,
Год журнала:
2023,
Номер
13(2), С. 259 - 259
Опубликована: Янв. 30, 2023
Coronavirus
disease
2019
(COVID-19),
caused
by
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
has
been
causing
a
worldwide
pandemic
since
2019.
Many
vaccines
have
manufactured
and
shown
promising
results
in
reducing
morbidity
mortality.
However,
variety
of
vaccine-related
adverse
effects,
including
hematological
events,
reported,
such
as
thromboembolic
thrombocytopenia,
bleeding.
Moreover,
new
syndrome,
vaccine-induced
immune
thrombotic
following
vaccination
against
COVID-19
recognized.
These
hematologic
side
effects
also
raised
concerns
about
SARS-CoV-2
patients
with
preexisting
conditions.
Patients
tumors
are
at
higher
risk
infection,
the
efficacy
safety
this
group
remain
uncertain
attention.
In
review,
we
discuss
events
disorders.
Vaccines,
Год журнала:
2023,
Номер
11(7), С. 1187 - 1187
Опубликована: Июль 1, 2023
We
develop
candidate
HIV-1
vaccines,
of
which
two
components,
ChAdOx1.tHIVconsv1
(C1)
and
ChAdOx1.HIVconsv62
(C62),
are
delivered
by
the
simian
adenovirus-derived
vaccine
vector
ChAdOx1.
Aberrant
adenovirus
RNA
splicing
involving
transgene(s)
coding
for
SARS-CoV-2
spike
was
suggested
as
an
aetiology
rare
adverse
events
temporarily
associated
with
initial
deployment
adenovirus-vectored
vaccines
during
COVID-19
pandemic.
Here,
to
eliminate
this
theoretically
plausible
phenomenon
from
list
possible
pathomechanisms
our
candidates,
we
directly
sequenced
mRNAs
in
C1-
C62-infected
nonpermissive
MRC-5
A549
permissive
HEK293
human
cell
lines.
Our
main
observations
cells,
most
similar
those
become
infected
after
intramuscular
administration
into
volunteers,
were
that
(i)
dominant
vector-derived
expected
transcripts
HIVconsvX
immunogens
(ii)
atypical
within
synthetic
open
reading
frame
transgenes
rare.
conclude
inadvertent
is
not
a
safety
concern
tested
vaccines.
Reports — Medical Cases Images and Videos,
Год журнала:
2023,
Номер
6(3), С. 42 - 42
Опубликована: Сен. 8, 2023
Paroxysmal
nocturnal
hemoglobinuria
(PNH)
is
a
clonal,
rare,
complement-mediated
hemolytic
anemia.
PNH
can
be
associated
with
marrow
failure
and
thrombophilia.
We
present
clinical
report
of
splenic
vein
thrombosis
in
patient
classic
PNH.
A
41-year-old
male
PNH,
naïve
to
complement
inhibitor
therapy,
developed
as
major
adverse
effect
after
vaccination
protocol
prevent
meningococcal
disease.
also
anticoagulant
eculizumab
treatment
outcomes.
In
patients,
should
monitored
outcome
events,
like
vaccine-induced
thrombosis.
Eculizumab
proves
effective
for
treating
intravascular
hemolysis
preventing
more
thrombotic
events.
The
potential
protective
role
on
controlling
activity
consequent
inflammation
may
help
the
not
experience
breakthrough
when
infected
SARS-CoV-2.
Extravascular
remains
present,
but
new
molecules
are
being
studied
inhibit
proximal
there
good
health
prospective
patients.
Since
the
reports
of
first
cases
COVID-19,
in
less
than
5
years
a
huge
number
documents
regarding
that
disease
and
coronavirus
(SARS-CoV-2),
responsible
for
infection,
have
been
published.
The
tremendous
scientific
covers
many
topics
on
different
issues
directly
related
to
COVID-19/SARS-CoV-2.
It
includes
studies
about
efficacy
vaccines
prevent
disease.
However,
only
comparatively
low
nonclinical
-conducted
experimental
animals-
focused
potential
adverse/toxic
effects
COVID-19
vaccines.
present
review
was
aimed
at
revising
literature
laboratory
animals
toxic/adverse
In
addition,
investigations
reported
those
specific
toxicology
journals
with
highest
impact
factors
examined
one
by
one.
results
indicate
most
nonclinical/experimental
and/or
candidates
showed
-in
general
terms-
good
safety
profile.
Only
some
animal
were
certain
adverse
found.
rather
surprising
result
has
limited
available
(in
databases
PubMed
Scopus)
performed
companies
largest
manufacturers
mRNA
world
[https://www.google.com/search?sca_esv=ba085665fbb45bd4&sca_upv=1&q=Who+is+the+largest+manufacturer+of+vaccines+in+the+world%3F&sa=X&sqi=2&ved=2ahUKEwj6nMbAi-qGAxVLaqQEHTPwDcIQzmd6BAgZEAY].
Why
these
-assuming,
course,
they
conducted-
not
published
journals,
allowing
judgment
international
community,
including
toxicologists?
